Regulating Off-Label Drug Use — Rethinking the Role of the FDA
- 3 April 2008
- journal article
- editorial
- Published by Massachusetts Medical Society in The New England Journal of Medicine
- Vol. 358 (14), 1427-1429
- https://doi.org/10.1056/nejmp0802107
Abstract
The Food and Drug Administration (FDA) provides a barrier to market entry and use of unproven and unsafe products. For prescription drugs, the FDA approval process requires substantial evidence of efficacy and safety for specific clinical situations. Although approval is indication-specific, the FDA has a limited role once a drug is on the market. Recent draft guidelines covering manufacturers' promotion of drugs through the distribution of journal articles suggest that the FDA is moving toward an even more minimal role.1Keywords
This publication has 2 references indexed in Scilit:
- Off-label Prescribing Among Office-Based PhysiciansArchives of Internal Medicine, 2006
- National Trends in Cyclooxygenase-2 Inhibitor Use Since Market ReleaseArchives of Internal Medicine, 2005